TipRanks
Swedish Orphan Biovitrum AB (GB:0MTD)
LSE:0MTD
UK Market
0MTD
Swedish Orphan Biovitrum AB
RESEARCH TOOLSreports

Swedish Orphan Biovitrum AB (0MTD) Share Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

0MTD Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Swedish
Orphan Biovitrum AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0MTD Stock 12 Month Forecast

Average Price Target

kr572.50
▲(24.26% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Swedish Orphan Biovitrum AB in the last 3 months. The average price target is kr572.50 with a high forecast of kr575.00 and a low forecast of kr570.00. The average price target represents a 24.26% change from the last price of kr460.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"294":"kr294","435":"kr435","576":"kr576","364.5":"kr364.5","505.5":"kr505.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr575.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":572.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr572.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":570,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr570.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[294,364.5,435,505.5,576],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,436.8,447.4307692307692,458.0615384615385,468.6923076923077,479.32307692307694,489.95384615384614,500.5846153846154,511.2153846153846,521.8461538461538,532.4769230769231,543.1076923076923,553.7384615384616,564.3692307692307,{"y":575,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,436.8,447.23846153846154,457.67692307692306,468.11538461538464,478.55384615384617,488.9923076923077,499.4307692307692,509.86923076923074,520.3076923076923,530.7461538461539,541.1846153846154,551.623076923077,562.0615384615385,{"y":572.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,436.8,447.04615384615386,457.2923076923077,467.53846153846155,477.7846153846154,488.03076923076924,498.2769230769231,508.5230769230769,518.7692307692307,529.0153846153846,539.2615384615385,549.5076923076923,559.7538461538461,{"y":570,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":295.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.929,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":331.283,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.345,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.641,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":407.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":434.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":467.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":470.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":457.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":436.8,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr575.00Average Price Targetkr572.50Lowest Price Targetkr570.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nordea Markets Analyst forecast on GB:0MTD
Mattias Haggblom
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
10/22/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at NordeaSwedish Orphan Biovitrum downgraded to Hold from Buy at Nordea
Berenberg Bank Analyst forecast on GB:0MTD
Harry Gillis
Berenberg Bank
Berenberg Bank
kr560→kr570
Buy
23.71%
Upside
Reiterated
10/19/26
Harry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth Upside
H.C. Wainwright Analyst forecast on GB:0MTD
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
kr575
Buy
24.80%
Upside
Reiterated
09/10/26
Sobi: Advancing Pacritinib Pipeline Supports Asymmetric Upside With Buy Rating and Maintained SEK575 Target
Deutsche Bank Analyst forecast on GB:0MTD
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr490→kr515
Buy
11.78%
Upside
Reiterated
07/21/26
Swedish Orphan Biovitrum price target raised to SEK 515 at Deutsche BankSwedish Orphan Biovitrum price target raised to SEK 515 at Deutsche Bank
Barclays Analyst forecast on GB:0MTD
James Gordon CFA
Barclays
Barclays
kr470→kr530
Buy
15.03%
Upside
Reiterated
07/03/26
Swedish Orphan price target raised to SEK 530 from SEK 470 at BarclaysSwedish Orphan price target raised to SEK 530 from SEK 470 at Barclays
Pareto Analyst forecast on GB:0MTD
Filip Wiberg
Pareto
Not Ranked
Pareto
kr470
Hold
2.01%
Upside
Downgraded
06/29/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at ParetoSwedish Orphan Biovitrum downgraded to Hold from Buy at Pareto
Kepler Capital Analyst forecast on GB:0MTD
Jon Berggren
Kepler Capital
Kepler Capital
kr350
Buy
-24.04%
Downside
Reiterated
04/29/26
Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
Danske Bank Analyst forecast on GB:0MTD
Gonzalo Artiach
Danske Bank
Not Ranked
Danske Bank
―
Hold
―
Downgraded
02/19/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske BankSwedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
Exane BNP Paribas Analyst forecast on GB:0MTD
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
kr475
Buy
3.10%
Upside
Upgraded
02/10/26
Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nordea Markets Analyst forecast on GB:0MTD
Mattias Haggblom
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
10/22/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at NordeaSwedish Orphan Biovitrum downgraded to Hold from Buy at Nordea
Berenberg Bank Analyst forecast on GB:0MTD
Harry Gillis
Berenberg Bank
Berenberg Bank
kr560→kr570
Buy
23.71%
Upside
Reiterated
10/19/26
Harry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth Upside
H.C. Wainwright Analyst forecast on GB:0MTD
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
kr575
Buy
24.80%
Upside
Reiterated
09/10/26
Sobi: Advancing Pacritinib Pipeline Supports Asymmetric Upside With Buy Rating and Maintained SEK575 Target
Deutsche Bank Analyst forecast on GB:0MTD
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr490→kr515
Buy
11.78%
Upside
Reiterated
07/21/26
Swedish Orphan Biovitrum price target raised to SEK 515 at Deutsche BankSwedish Orphan Biovitrum price target raised to SEK 515 at Deutsche Bank
Barclays Analyst forecast on GB:0MTD
James Gordon CFA
Barclays
Barclays
kr470→kr530
Buy
15.03%
Upside
Reiterated
07/03/26
Swedish Orphan price target raised to SEK 530 from SEK 470 at BarclaysSwedish Orphan price target raised to SEK 530 from SEK 470 at Barclays
Pareto Analyst forecast on GB:0MTD
Filip Wiberg
Pareto
Not Ranked
Pareto
kr470
Hold
2.01%
Upside
Downgraded
06/29/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at ParetoSwedish Orphan Biovitrum downgraded to Hold from Buy at Pareto
Kepler Capital Analyst forecast on GB:0MTD
Jon Berggren
Kepler Capital
Kepler Capital
kr350
Buy
-24.04%
Downside
Reiterated
04/29/26
Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
Danske Bank Analyst forecast on GB:0MTD
Gonzalo Artiach
Danske Bank
Not Ranked
Danske Bank
―
Hold
―
Downgraded
02/19/26
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske BankSwedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
Exane BNP Paribas Analyst forecast on GB:0MTD
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
kr475
Buy
3.10%
Upside
Upgraded
02/10/26
Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Swedish Orphan Biovitrum AB

3 Months
Harry GillisBerenberg Bank
Success Rate
16/22 ratings generated profit
73%
Average Return
+5.48%
Copying Harry Gillis's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +5.48% per trade.
1 Year
Harry GillisBerenberg Bank
Success Rate
20/22 ratings generated profit
91%
Average Return
+15.08%
Copying Harry Gillis's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +15.08% per trade.
2 Years
Harry GillisBerenberg Bank
Success Rate
20/22 ratings generated profit
91%
Average Return
+32.92%
Copying Harry Gillis's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +32.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0MTD Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
9
10
10
10
7
Hold
1
1
1
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
11
11
10
8
In the current month, 0MTD has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0MTD average Analyst price target in the past 3 months is 572.50.
Each month's total comprises the sum of three months' worth of ratings.

0MTD Financial Forecast

0MTD Earnings Forecast

Next quarter’s earnings estimate for 0MTD is kr6.01 with a range of kr5.48 to kr6.51. The previous quarter’s EPS was kr3.14. 0MTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0MTD has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0MTD is kr6.01 with a range of kr5.48 to kr6.51. The previous quarter’s EPS was kr3.14. 0MTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0MTD has Performed in-line its overall industry.

0MTD Sales Forecast

Next quarter’s sales forecast for 0MTD is kr8.95B with a range of kr8.68B to kr9.43B. The previous quarter’s sales results were kr7.84B. 0MTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0MTD has Performed in-line its overall industry.
Next quarter’s sales forecast for 0MTD is kr8.95B with a range of kr8.68B to kr9.43B. The previous quarter’s sales results were kr7.84B. 0MTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0MTD has Performed in-line its overall industry.

0MTD Stock Forecast FAQ

What is GB:0MTD’s average 12-month price target, according to analysts?
Based on analyst ratings, Swedish Orphan Biovitrum AB’s 12-month average price target is 572.50.
    What is GB:0MTD’s upside potential, based on the analysts’ average price target?
    Swedish Orphan Biovitrum AB has 24.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Swedish Orphan Biovitrum AB a Buy, Sell or Hold?
          Swedish Orphan Biovitrum AB has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Swedish Orphan Biovitrum AB’s share price target?
            The average share price target for Swedish Orphan Biovitrum AB is 572.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr575.00 ,and the lowest forecast is kr570.00. The average share price target represents 24.26% Increase from the current price of kr460.74.
              What do analysts say about Swedish Orphan Biovitrum AB?
              Swedish Orphan Biovitrum AB’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Swedish Orphan Biovitrum AB?
                To buy shares of GB:0MTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.